Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2012

View Archived Issues

Cardiosphere-derived autologous stem cells tested in patients with myocardial infarction

U.S. scientists design logic-gated DNA nanorobots for targeted drug delivery

Novel USP14 inhibitors presented by Harvard College

Bayer Schering Pharma discloses new soluble guanylate cyclase inhibitors

Boehringer Ingelheim patents new cannabinoid CB2 receptor ligands

Cephalon prepares novel IL-23-binding proteins

Novel antimalarial vaccines designed at Polish university

SGX-202 shows promise in model of gastrointestinal acute radiation syndrome

Gentium responds to EMA's day 120 list of questions for defibrotide MAA

S1 Pharmaceuticals submits IND application for SIP-104

Oral cardiac muscle myosin activator enters phase I trial

Jubilant and Mnemosyne enter collaboration

Full BOLERO-2 study results published

FDA grants priority review to Repligen NDA

Canadian distribution agreement set for tesamorelin

PCI Biotech begins treatment in Amphinex study

Ligand Pharmaceuticals enters new licensing agreement

Nuvo Research provides regulatory update on anesthetic cream

Nippon Kayaku anticancer drugs approved for additional indications in Japan

Preparations begin for European trial of NX-1207

Phase II/III trial to evaluate RLX-030 following acute heart failure

New site added to phase II trial of Telcyta

Novartis seeks line extension for Diovan

Salix begins phase III trial to assess repeated rifaximin treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...